OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer
Stock Information for OncoSec Medical Incorporated
Loading
Please wait while we load your information from QuoteMedia.